TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30590810

Group type: EXPERIMENTAL
Intervention: Group-delivered Acceptance and Commitment Therapy (ACT)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Group-delivered Cognitive Behavioral Therapy (CBT)
Number of subjects: 450
Study: 31318868

Group type: EXPERIMENTAL
Intervention: Self-Regulation Strategy Development (SRSD) instruction
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: SRSD plus Self-Regulated Learning (SRL) program using a story-tool
Number of subjects: 370

Group type: COMPARATOR
Intervention: Week-journals
Number of subjects: 370

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 370
Study: 27873152

Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart (faster aspart)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Insulin Aspart (IAsp)
Number of subjects: 30
Study: 25142778

Group type: EXPERIMENTAL
Intervention: Laropiprant 100mg once daily for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 23437385

Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation (tDCS) applied to M1
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham stimulation (control)
Number of subjects: 16
Study: 22134570

Group type: EXPERIMENTAL
Intervention: Rupatadine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Levocetirizine
Number of subjects: 70
Study: 19243886

Group type: EXPERIMENTAL
Intervention: Selective ligature of DVC (SLDVC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard ligature of DVC
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study: 16380237

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (quetiapine, olanzapine, risperidone, clozapine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Typical antipsychotics (haloperidol, chlorpromazine)
Number of subjects: 0
Study: 14725594

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN alpha) immunotherapy
Number of subjects: 0
Study: 11240088

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral return-to-work program
Number of subjects: 72

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 72
Study: 9769277

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms inhaled 15 min prior to L-ASA challenge)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (inhaled 15 min prior to L-ASA challenge)
Number of subjects: 10
Study: 7508697

Group type: EXPERIMENTAL
Intervention: Rocuronium 600 micrograms/kg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Rocuronium 900 micrograms/kg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Rocuronium 1200 micrograms/kg
Number of subjects: 3
Study: 2826714

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, doxorubicin, and cisplatin (CAP) followed by mitomycin, lomustine, and methotrexate (MCM) on progression (sequential)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Cyclophosphamide, doxorubicin, and cisplatin (CAP) alternating with mitomycin, lomustine, and methotrexate (MCM) (alternating)
Number of subjects: 108
Study: 31416695

Group type: EXPERIMENTAL
Intervention: Pump On (50% basal insulin at exercise onset)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pump Off (0% basal insulin at exercise onset)
Number of subjects: 12
Study: 30194668

Group type: EXPERIMENTAL
Intervention: MoVo‐LISA intervention group (IG)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 83
Study: 28347256

Group type: EXPERIMENTAL
Intervention: Sleep deprivation (1 night of total sleep deprivation)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal sleep control night
Number of subjects: 32
Study: 25554993

Group type: EXPERIMENTAL
Intervention: Internet-based preventive program adjunctive to usual pharmacological management
Number of subjects: 233

Group type: COMPARATOR
Intervention: Attention control treatment (directing subjects to healthy living websites)
Number of subjects: 233
Study: 23877341

Group type: EXPERIMENTAL
Intervention: TARGIT (intra‐operative radiotherapy with Intrabeam(®))
Number of subjects: 342

Group type: COMPARATOR
Intervention: Conventional external beam radiotherapy (EBRT)
Number of subjects: 342
Study: 21978765

Group type: COMPARATOR
Intervention: Gemcitabine plus carboplatin (GC) - gemcitabine 1,000 mg/m² on days 1 and 8, plus carboplatin AUC 5 on day 1, every 21 days for up to six cycles.
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin (TC) - paclitaxel 175 mg/m² plus carboplatin AUC 6 on day 1, every 21 days for up to six cycles.
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Paclitaxel consolidation therapy - 135 mg/m² every 28 days for ≤ 12 months, for patients with complete response (CR).
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Single-agent crossover therapy for patients without CR, at induction doses/schedules until CR, disease progression (PD), or unacceptable toxicity.
Number of subjects: 919
Study: 18547152

Group type: EXPERIMENTAL
Intervention: 1 cartridge lidocaine/epinephrine followed after 30 minutes by 1 cartridge phentolamine (1L1P)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1 cartridge phentolamine administered intravenously (1Piv)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 4 cartridges lidocaine/epinephrine followed after 30 minutes by 2 cartridges phentolamine (4L2P)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 4 cartridges lidocaine/epinephrine followed by no phentolamine (4L)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Comparison of pharmacokinetic parameters for phentolamine, lidocaine, and epinephrine
Number of subjects: 16
Study: 16939026

Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiation (80mJ/2Hz) for 20s at 11mm distance
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiation (80mJ/2Hz) for 20s at 12mm distance
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiation (80mJ/2Hz) for 20s at 14mm distance
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiation (80mJ/2Hz) for 20s at 16mm distance
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiation (80mJ/2Hz) for 20s at 17mm distance
Number of subjects: 60

Group type: COMPARATOR
Intervention: Phosphoric acid application for 15 seconds (control group)
Number of subjects: 60
Study: 12559677

Group type: EXPERIMENTAL
Intervention: Efonidipine
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 68
Study: 11041584

Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Home exercises
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 96
Study: 9124194

Group type: EXPERIMENTAL
Intervention: Chemotherapy and filgrastim (5 microg/kg/day s.c.)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Chemotherapy alone (control group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Chemotherapy and filgrastim (level 3: day 4 to day 7 and day 10 to day 13)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Chemotherapy and filgrastim
Number of subjects: 24
Study: 8438597

Group type: EXPERIMENTAL
Intervention: Daily supplements of 26 ml water/kg body weight and 0.16 g sodium chloride/kg body weight during hypokinesia
Number of subjects: 18

Group type: COMPARATOR
Intervention: Continuous restriction of motor activity without supplementation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normal ambulatory life (control subjects)
Number of subjects: 18
Study: 3462335

Group type: EXPERIMENTAL
Intervention: Oral melatonin administration in 8 SAD patients
Number of subjects: 34

Group type: COMPARATOR
Intervention: Atenolol (beta-adrenergic blocker) in 19 SAD patients
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Phototherapy in 7 SAD patients
Number of subjects: 34
Study: 30115087

Group type: EXPERIMENTAL
Intervention: Follow in my Green Food Steps programme (Intervention)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Control (no information provided)
Number of subjects: 602
Study: 27142462

Group type: EXPERIMENTAL
Intervention: Stem cell transplantation (SCT)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Melphalan plus dexamethasone
Number of subjects: 89

Group type: COMPARATOR
Intervention: Matched analysis (SCT vs melphalan plus dexamethasone)
Number of subjects: 89
Study: 25740399

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 109

Group type: COMPARATOR
Intervention: Carperitide
Number of subjects: 109
Study: 23403087

Group type: EXPERIMENTAL
Intervention: TCRE plus gestagen
Number of subjects: 71

Group type: COMPARATOR
Intervention: TCRE alone
Number of subjects: 71
Study: 20620365

Group type: EXPERIMENTAL
Intervention: Lava Frame 0.3 mm thick
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Lava Frame 0.5 mm thick
Number of subjects: 9

Group type: COMPARATOR
Intervention: Lithium disilicate glass-ceramic (control)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: All ZrO(2) copings
Number of subjects: 9
Study: 18632272

Group type: EXPERIMENTAL
Intervention: Electro-tactile vestibular substitution system (EVSS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No-EVSS
Number of subjects: 12
Study: 15913898

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral coping skills therapy combined with pharmacotherapy
Number of subjects: 80
Study: 12421055

Group type: EXPERIMENTAL
Intervention: Smaller-group search
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Explicit instructions to limit search to a specific feature
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Bottom-up factors
Number of subjects: 6
Study: 10340838

Group type: EXPERIMENTAL
Intervention: 75 mg/day aspirin (n = 9399)
Number of subjects: 18790

Group type: COMPARATOR
Intervention: Placebo (n = 9391)
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Target DBP < or = 90 mmHg (n = 6264)
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Target DBP < or = 85 mmHg (n = 6264)
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Target DBP < or = 80 mmHg (n = 6262)
Number of subjects: 18790
Study: 7594023

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 408
Study: 1823041

Group type: EXPERIMENTAL
Intervention: Nd-YAG laser treatment
Number of subjects: 117
Study: 7025334

Group type: EXPERIMENTAL
Intervention: Exercise training (6 weeks in a rehabilitation centre followed by home continuation)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (attended rehabilitation centre after the controlled part of the study)
Number of subjects: 39
Study: 30232627

Group type: EXPERIMENTAL
Intervention: Titanium curettes (TC)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Stainless steel ultrasonic tip (PS)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Erythritol air-polishing powder (EP)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Rubber cup polishing (CON)
Number of subjects: 8
Study: 27957785

Group type: EXPERIMENTAL
Intervention: 2R/2R genotype of thymidylate synthase (TS)
Number of subjects: 615

Group type: COMPARATOR
Intervention: Control group (non-2R/2R genotypes)
Number of subjects: 615
Study: 25676904

Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 24417878

Group type: EXPERIMENTAL
Intervention: Loss-framed message with attained outcomes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other message frames (gain-framed, loss-framed with undesirable outcomes, etc.)
Number of subjects: 0
Study: 21674768

Group type: EXPERIMENTAL
Intervention: Cefoperazone-sulbactam (CS) 100 mg/kg/day
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam (PIP/TAZO) 360 mg/kg/day
Number of subjects: 55
Study: 19358075

Group type: EXPERIMENTAL
Intervention: Cortisone injection
Number of subjects: 57

Group type: COMPARATOR
Intervention: Local anaesthetics injection
Number of subjects: 57
Study: 17440204

Group type: EXPERIMENTAL
Intervention: Presence of noise (negative noise) in social-ecological interaction
Number of subjects: 0

Group type: COMPARATOR
Intervention: No noise (control condition)
Number of subjects: 0
Study: 11190521

Group type: EXPERIMENTAL
Intervention: Colon-J-pouch anal anastomosis (CPAA)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Straight side-to-end colo-anal anastomosis (CAA)
Number of subjects: 66
Study: 3161813

Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated estrogens (CE) daily
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 150 mg of intramuscular depomedroxyprogesterone acetate (DMPA) every 3 months
Number of subjects: 17

Group type: COMPARATOR
Intervention: Premenopausal controls
Number of subjects: 17
Study: 30538063

Group type: EXPERIMENTAL
Intervention: Same-admission cholecystectomy
Number of subjects: 249

Group type: COMPARATOR
Intervention: Delayed cholecystectomy (after 2 weeks)
Number of subjects: 249
Study: 29055158

Group type: EXPERIMENTAL
Intervention: 1.85% UMEC
Number of subjects: 23

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 23
Study: 28383836

Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium 110/50 μg (IND/GLY) once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salmeterol/proprionate of fluticasone 50/500 μg (SAL/FC) twice daily
Number of subjects: 0
Study: 25047458

Group type: EXPERIMENTAL
Intervention: edoxaban 15 mg once daily
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: edoxaban 30 mg once daily
Number of subjects: 264

Group type: COMPARATOR
Intervention: enoxaparin 2000 IU (20 mg) twice daily
Number of subjects: 264
Study: 22171728

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT), 6 sessions
Number of subjects: 58

Group type: COMPARATOR
Intervention: Nutrition-focused attention-matched control group (CG), 6 sessions
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both groups (CBT and CG)
Number of subjects: 58
Study: 20686456

Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injectable (RLAI)
Number of subjects: 666

Group type: COMPARATOR
Intervention: Oral quetiapine
Number of subjects: 666
Study: 18454611

Group type: EXPERIMENTAL
Intervention: Single music therapy intervention
Number of subjects: 25

Group type: COMPARATOR
Intervention: Volunteer visit (control group)
Number of subjects: 25
Study: 16162051

Group type: EXPERIMENTAL
Intervention: Stereotype-consistent views
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stereotype-inconsistent views
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High affiliative motivation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social distance motives
Number of subjects: 0
Study: 12527977

Group type: EXPERIMENTAL
Intervention: 15-Pre (75 g glucose dissolved in 500 ml water, ingested 15 min before exercise)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 45-Pre (75 g glucose dissolved in 500 ml water, ingested 45 min before exercise)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 75-Pre (75 g glucose dissolved in 500 ml water, ingested 75 min before exercise)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 15-Pre
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 45-Pre
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 75-Pre
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 15-Pre, 45-Pre, 75-Pre
Number of subjects: 8
Study: 10231449

Group type: EXPERIMENTAL
Intervention: L-arginine (17 mg/kg/min over 30 min)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (1.0 microgram/kg/min over 30 min)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 35
Study: 8910967

Group type: EXPERIMENTAL
Intervention: Threshold models applied in methadone programme evaluation
Number of subjects: 0
Study: 1907091

Group type: EXPERIMENTAL
Intervention: Glucose alone
Number of subjects: 7

Group type: COMPARATOR
Intervention: Glucose-lipid mixture
Number of subjects: 7
Study: 29077900

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 27466218

Group type: EXPERIMENTAL
Intervention: Exenatide (EXE) twice daily (BID)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Insulin glargine (GLAR)
Number of subjects: 69
Study: 24342024

Group type: EXPERIMENTAL
Intervention: 12-step attendance during years 1 and 5
Number of subjects: 1945

Group type: EXPERIMENTAL
Intervention: Treatment duration
Number of subjects: 1945
Study: 23216646

Group type: EXPERIMENTAL
Intervention: NicVAX® co-administered with varenicline (Champix®)
Number of subjects: 600

Group type: COMPARATOR
Intervention: placebo co-administered with varenicline (Champix®)
Number of subjects: 600
Study: 20405011

Group type: EXPERIMENTAL
Intervention: Directly observed highly-active antiretroviral therapy (DOT)
Number of subjects: 1000000

Group type: EXPERIMENTAL
Intervention: Self-administered HAART
Number of subjects: 1000000

Group type: COMPARATOR
Intervention: No HAART
Number of subjects: 1000000

Group type: EXPERIMENTAL
Intervention: Directly observed therapy (DOT)
Number of subjects: 1000000
Study: 18676757

Group type: EXPERIMENTAL
Intervention: ALVAC-CEA/B7.1 vaccine followed by chemotherapy (group 1)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: ALVAC-CEA/B7.1 vaccine with tetanus toxoid adjuvant followed by chemotherapy (group 2)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by ALVAC-CEA/B7.1 vaccine (group 3)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Overall treatment (all groups)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Chemotherapy alone (group 3)
Number of subjects: 118
Study: 16425972

Group type: COMPARATOR
Intervention: Calcipotriol monotherapy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Calcipotriol plus UVA1 phototherapy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Calcipotriol plus narrow-band UVB phototherapy
Number of subjects: 45
Study: 15463842

Group type: EXPERIMENTAL
Intervention: Zafirlukast 20 mg twice daily with routine treatment for four months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine treatment alone
Number of subjects: 30
Study: 10816408

Group type: EXPERIMENTAL
Intervention: Buscopan (hyoscine-N-butylbromide) 20 mg administered before barium infusion (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Buscopan (hyoscine-N-butylbromide) 20 mg administered after barium infusion and gas insufflation (Group B)
Number of subjects: 100
Study: 8666605

Group type: EXPERIMENTAL
Intervention: Preoperative irradiation (800 centigray dose)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Postoperative irradiation (800 centigray dose)
Number of subjects: 85
Study: 1876282

Group type: EXPERIMENTAL
Intervention: Intravenous amino acid infusion (90 min)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous amino acid infusion (30 min)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous amino acid infusion (both protocols)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous amino acid infusion
Number of subjects: 24
Study: 6871775

Group type: EXPERIMENTAL
Intervention: Succinylcholine 2% solution
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Succinylcholine 5% solution
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study: 30721937

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS)
Number of subjects: 966

Group type: COMPARATOR
Intervention: Non-LNS (multiple micronutrient (MMN) + iron and folic acid (IFA))
Number of subjects: 966
Study: 27795368

Group type: EXPERIMENTAL
Intervention: MEDI4893 at 225 mg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: MEDI4893 at 750 mg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: MEDI4893 at 2,250 mg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: MEDI4893 at 5,000 mg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: MEDI4893
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 26651384

Group type: EXPERIMENTAL
Intervention: Customized foot orthoses
Number of subjects: 0
Study: 25170833

Group type: EXPERIMENTAL
Intervention: GH(67) (67 µg/kg/day)
Number of subjects: 111

Group type: COMPARATOR
Intervention: GH(33×1) (33 µg/kg/day)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: GH(67×1) (67 µg/kg/day)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: GH(33×2) (67 µg/kg/day)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: GH(67)
Number of subjects: 111

Group type: COMPARATOR
Intervention: GH(33)
Number of subjects: 111
Study: 23082835

Group type: EXPERIMENTAL
Intervention: Graphic warnings showing cosmetically important harm caused by smoking
Number of subjects: 56

Group type: COMPARATOR
Intervention: Written smoking warnings alone
Number of subjects: 56
Study: 18615103

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) treatment
Number of subjects: 22
Study: 17683094

Group type: EXPERIMENTAL
Intervention: Family-based therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Individual-supportive psychotherapy
Number of subjects: 80
Study: 15449046

Group type: EXPERIMENTAL
Intervention: 6-h IDEX SPECT scan
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0-h IDEX SPECT scan
Number of subjects: 12

Group type: COMPARATOR
Intervention: 3-h IDEX SPECT scan
Number of subjects: 12

Group type: COMPARATOR
Intervention: 24-h IDEX SPECT scan
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IDEX SPECT
Number of subjects: 12

Group type: COMPARATOR
Intervention: MR imaging
Number of subjects: 12
Study: 12222721

Group type: EXPERIMENTAL
Intervention: Standardized sleep programme with therapist support
Number of subjects: 67

Group type: COMPARATOR
Intervention: Written information only during the first intervention
Number of subjects: 67
Study: 9472974

Group type: EXPERIMENTAL
Intervention: Indomethacin 150 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7617236

Group type: EXPERIMENTAL
Intervention: Oral diazepam 0.1 mg x kg‐1 + oral clonidine 5 micrograms x kg‐1 (Group B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral diazepam 0.1 mg x kg‐1 + i.m. clonidine 4 micrograms x kg‐1 (Group C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral diazepam 0.1 mg x kg‐1 (Group A)
Number of subjects: 30
Study: 2611446

Group type: EXPERIMENTAL
Intervention: 200 IU of salmon calcitonin nasal spray (sCT‐NS)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 400 IU of salmon calcitonin nasal spray (sCT‐NS)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 330322

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide + triamterene treatment with or without methyldopa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initiation of hypotensive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypotensive therapy
Number of subjects: 0